• Dr. Raimon Puig de la Bellacasa Cazorla

Dr. Raimon Puig de la Bellacasa Cazorla

Organic and Pharmaceutical Chemistry Department

IQS School of Engineering

Universitat Ramon Llull

Via Augusta 390, E-08017 Barcelona, Spain

Tel.: +34 932 672 000 ext. 2342

Fax: +34 939 056 266

email: 
raimon.puig@iqs.url.edu

Degree in Chemistry, organic chemistry intensification (URL, 2004).

Chemical Engineer Degree at Institut Químic de Sarrià (IQS, 2007).

Master of Advanced Studies (DEA) (URL, 2008).

PhD in Chemistry (Organic Chemistry, Universitat Ramon Llull (URL), 2010).

Postdoctoral Researcher at Institut Químic de Sarrià (Prof. J. I. Borrell, URL, 2010-2012)

Research Collaborator (IQS-Pangaea Biotech S. L., 2013-2017)

Research stay at Boston College (Prof. S.-Y Liu, Boston, EE.UU., June-September 2017)

Assistant Lecturer (IQS, 2018- )

 

Fundaments on Chemical and Biological Laboratories (Degrees in Chemistry and Chemical Engineering)

Laboratory 1+2 (Chemistry and Biology) (Degree in Biotechnology)

Chemistry (Degree in Industrial Technologies Engineering)

Laboratory in Pharmaceutical Chemistry (Degree in Pharmacy)

 

Synthesis and biological evaluation of new heterocyclic structures with inhibitory capability of G Protein-Coupled Receptors (GPCR), Tyrosine Kinases (TK) and Tyrosine Kinase Receptors (RTK) to treat Cancer, HIV (AIDS), HCV (Hepatitis) and Myotonic Dystrophy.

 

E. Bou-Petit, E. Picas, C. Puigjaner, M. Font-Bardia, N. Ferrer, J. Sempere, R. Puig de la Bellacasa, X. Batllori, J. Teixidó, R. Estrada-Tejedor, S. Ramon y Cajal, J. I. Borrell. An unequivocal synthesis of 2-aryl substituted 3-amino-2,4,5,7-tetrahydro-6H-pyrazolo[3,4-b]pyridin-6-ones. ChemistrySelect, 2017, 2, 3668-3672.

I. Chaib, N. Karachaliou, S. Pilotto, J. Codony Servat, X. Cai, X. Li, A. Drozdowskyj, C. Codony Servat, J. Yang, C. Hu, A. F. Cardona, G. Lopez Vivanco, A. Vergnenegre, J. M. Sanchez, M. Provencio, F. de Marinis, A. Passaro, E. Carcereny, N. Reguart, C. Garcia Campelo, C. Teixidó, I. Sperduti, S. Rodriguez, C. Lazzari, A. Verlicchi, I. de Aguirre, C. Queralt, J. Wei, R. Estrada, R. Puig de la Bellacasa, J. L. Ramirez, K. Jacobsen, H. J. Ditzel, M. C. Santarpia, S. Viteri, M. A. Molina, C. Zhou, P. Cao, P. C. Ma, T. G. Bivona, R. Rosell.Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC. J Natl. Cancer Inst., 2017, 109(9).

P. Balsas, A. Esteve-Arenys, J. Roldán, L. Jiménez, V. Rodríguez, J. G. Valero, A. Chamorro-Jorganes, R. Puig de la Bellacasa, J. Teixidó, A. Matas-Céspedes, A. Moros, A. Martínez, E. Campo, A. Sáez-Borderías, J. I. Borrell, P. Pérez-Galán, D. Colomer, G. Roué. Activity of the novel BCR kinase inhibitor IQS019 in preclinical models of B-cell non-Hodgkin lymphoma Journal of Hematology & Oncology, 2017, 10:80.

5-Amino-6,7,8,9-Tetrahydrobenzo[b][1,8]Naphthyridin-2-(1H)-one: The first Example of a new Family of HuperTacrines for Alzheimer’s Disease Therapy. A. Balmori, M. Chioua, R. Puig de la Bellacasa, R. Estrada-Tejedor, L. Ismaili, J. Marco-Contelles, J. I. Borrell. Chemistry Select, 2017, 2, 2605-2610.

M. Camarasa, R. Puig de la Bellacasa, A. L. González, R. Ondoño, R. Estrada, S. Franco, R. Badia, J. Esté, M. Á. Martínez, J. Teixidó, B. Clotet, J. I. Borrell. Design, synthesis and biological evaluation of pyrido[2,3-d]pyrimidin-7-(8H)-ones as HCV inhibitors Eur. J. Med. Chem., 2016, 115, 463-483.

M. J. Lavecchia, R. Puig de la Bellacasa, J. I. Borrell, C. N. Cavasotto. Investigating molecular dynamics-guided lead optimization of EGFR inhibitors. Bioorg. Med. Chem., 2016, 24, 768-778.

R. Puig de la Bellacasa, A. Gibert, J. M. Planesas, L. Ros-Blanco, X. Batllori, R. Badía, B. Clotet, J. Esté, J. Teixidó, J. I. Borrell. Nitrogen positional scanning in tetramines active against HIV-1 as potential CXCR4 inhibitors. Org. Biomol. Chem., 2016, 14, 1455-1472.

M. Chioua, M. Pérez, O. M. Bautista-Aguilera, M. Yañez, M. G. López, A. Romero, R. Cacabelos, R. Puig de la Bellacasa, S. Brogi, S. Butini, J. I. Borrell, J. Marco-Contelles. Development of HuperTacrines as Non-Toxic, Cholinesterase Inhibitors for the Potential Treatment of Alzheimer’s Disease. Mini-Reviews in Medicinal Chemistry, 2015, 15(8), 648-658.

R. Puig de la Bellacasa, G. Roué, P. Balsas, P. Pérez-Galán, J. Teixidó, D. Colomer, J. I. Borrell. 4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies Eur. J. Med. Chem., 2014, 86, 664-675.

R. Puig de la Bellacasa, N. Karachaliou, R. Estrada-Tejedor, J. Teixidó, C. Costa, J. I. Borrell. ALK and ROS1 as a joint target for the treatment of lung cancer: a review. Translational Lung Cancer Research, 2013, 2(2), 72-86.

M. Camarasa, C. Barnils, R. Puig de la Bellacasa, J. Teixidó, J. I. Borrell. A new and practical method for the synthesis of 6-aryl-5,6-dihydropyrido[2,3-d]pyrimidine- 4,7(3H,8H)-diones. Mol. Divers., 2013, 17(3), 525-536.

I. Galve, R. Puig de la Bellacasa, D. Sánchez-García, X. Batllori, J. Teixidó, J. I. Borrell. Synthesis of 2-arylamino substituted 5,6-dihydropyrido[2,3-d]pyrimidine-7(8H)-ones from arylguanidines. Mol. Divers., 2012, 16(4), 639-649.

R. Puig-de-la-Bellacasa, L. Giménez, S. Pettersson, R. Pascual, E. Gonzalo, J. A. Esté, B. Clotet, J. I. Borrell, J. Teixidó. Diverse combinatorial design, synthesis and in vitro evaluation of new HEPT analogues as potential non-nucleoside HIV-1 reverse transcription inhibitors. Eur. J. Med. Chem., 2012, 54, 159-174.

S. Pettersson, V. I. Pérez-Nueno, L. Ros-Blanco, R. Puig de la Bellacasa, M. Obdulia Rabal, X. Batllori, B. Clotet, I. Clotet-Codina, M. Armand-Ugón, J. Esté, J. I. Borrell, J. Teixidó. Discovery of Novel Non-Cyclam Polynitrogenated CXCR4 Coreceptors Inhibitors. ChemMedChem., 2008, 3 (10), 1549-1557.

 

Pharmaceutical Chemistry Group (GQF)